27625705|t|Gut microbiome alterations in patients with stage 4 hepatitis C
27625705|a|Hepatitis C virus (HCV) causes debilitating liver diseases, which may progress to cirrhosis and cancer, and claims 500,000 annual lives worldwide. While HCV epidemiology, pathophysiology, and therapy are being deeply studied, rare attention is given to reciprocal interactions between HCV infection, HCV -induced chronic liver diseases, and the human gut microbiome. As Egypt has the world's highest prevalence of HCV infections, we launched this study to monitor differences in the gut microbial community composition of Egyptian HCV patients that may affect, or result from, the patients ' liver state. To this end, we analyzed stool samples from six stage 4 - HCV patients and eight healthy individuals by high-throughput 16S rRNA gene sequencing using Illumina MiSeq. Overall, the alpha-diversity of the healthy persons' gut microbiomes was higher than those of the HCV patients. Whereas members of phylum Bacteroidetes were more abundant in HCV patients, healthy individuals had higher abundance of Firmicutes, Proteobacteria, and Actinobacteria. Genus -level analysis showed differential abundance of Prevotella and Faecalibacterium (higher in HCV patients) vs. Ruminococcus and Clostridium (healthy group), indicating that the higher abundance of Bacteroidetes in HCV patients is most likely due to Prevotella overabundance. The probiotic genus, Bifidobacterium, was only observed in the microbiotas of healthy individuals. To the best of our knowledge, this study provides a first overview of major phyla and genera differentiating stage 4 - HCV patients from healthy individuals and suggests possible microbiome remodeling in chronic hepatitis C, possibly shaped by bacterial translocation as well as the liver's impaired role in digestion and protein synthesis. Future studies will investigate the microbiome composition and functional capabilities in more patients while tracing some potential biomarker taxa (e.g., Prevotella, Faecalibacterium vs. Bifidobacterium).
27625705	52	63	hepatitis C	T038	UMLS:C0019196
27625705	64	81	Hepatitis C virus	T005	UMLS:C0220847
27625705	83	86	HCV	T005	UMLS:C0220847
27625705	108	122	liver diseases	T038	UMLS:C0023895
27625705	146	155	cirrhosis	T038	UMLS:C0023890
27625705	160	166	cancer	T038	UMLS:C0006826
27625705	217	220	HCV	T005	UMLS:C0220847
27625705	221	233	epidemiology	T062	UMLS:C0002783
27625705	235	250	pathophysiology	T038	UMLS:C0277785
27625705	317	340	reciprocal interactions	T038	UMLS:C0596935
27625705	349	362	HCV infection	T038	UMLS:C4288963
27625705	364	367	HCV	T005	UMLS:C0220847
27625705	377	399	chronic liver diseases	T038	UMLS:C0341439
27625705	409	414	human	T204	UMLS:C0086418
27625705	434	439	Egypt	T082	UMLS:C0013715
27625705	448	455	world's	T098	UMLS:C2700280
27625705	478	492	HCV infections	T038	UMLS:C4288963
27625705	511	516	study	T062	UMLS:C2603343
27625705	571	582	composition	T201	UMLS:C0486616
27625705	586	594	Egyptian	T098	UMLS:C0337801
27625705	595	598	HCV	T005	UMLS:C0220847
27625705	656	661	liver	T017	UMLS:C0023884
27625705	694	707	stool samples	T031	UMLS:C1550661
27625705	727	730	HCV	T005	UMLS:C0220847
27625705	750	769	healthy individuals	T098	UMLS:C1708335
27625705	789	813	16S rRNA gene sequencing	T058	UMLS:C1294197
27625705	820	834	Illumina MiSeq	T074	UMLS:C0348000
27625705	872	888	healthy persons'	T098	UMLS:C1708335
27625705	934	937	HCV	T005	UMLS:C0220847
27625705	967	987	phylum Bacteroidetes	T007	UMLS:C0995456
27625705	1010	1013	HCV	T005	UMLS:C0220847
27625705	1024	1043	healthy individuals	T098	UMLS:C1708335
27625705	1068	1078	Firmicutes	T007	UMLS:C1254144
27625705	1080	1094	Proteobacteria	T007	UMLS:C0751985
27625705	1100	1114	Actinobacteria	T007	UMLS:C0600148
27625705	1116	1121	Genus	T170	UMLS:C1708235
27625705	1129	1137	analysis	T062	UMLS:C0936012
27625705	1171	1181	Prevotella	T007	UMLS:C0242946
27625705	1186	1202	Faecalibacterium	T007	UMLS:C1229075
27625705	1214	1217	HCV	T005	UMLS:C0220847
27625705	1232	1244	Ruminococcus	T007	UMLS:C0318074
27625705	1249	1260	Clostridium	T007	UMLS:C0009054
27625705	1318	1331	Bacteroidetes	T007	UMLS:C0995456
27625705	1335	1338	HCV	T005	UMLS:C0220847
27625705	1370	1380	Prevotella	T007	UMLS:C0242946
27625705	1400	1415	probiotic genus	T007	UMLS:C0525033
27625705	1417	1432	Bifidobacterium	T007	UMLS:C0005380
27625705	1474	1493	healthy individuals	T098	UMLS:C1708335
27625705	1530	1535	study	T062	UMLS:C2603343
27625705	1571	1576	phyla	T170	UMLS:C1709533
27625705	1581	1587	genera	T170	UMLS:C1708235
27625705	1614	1617	HCV	T005	UMLS:C0220847
27625705	1632	1651	healthy individuals	T098	UMLS:C1708335
27625705	1699	1718	chronic hepatitis C	T038	UMLS:C0524910
27625705	1739	1762	bacterial translocation	T038	UMLS:C0282583
27625705	1778	1785	liver's	T017	UMLS:C0023884
27625705	1786	1799	impaired role	T033	UMLS:C0231410
27625705	1803	1812	digestion	T038	UMLS:C0012238
27625705	1817	1834	protein synthesis	T038	UMLS:C0597295
27625705	1883	1894	composition	T201	UMLS:C0486616
27625705	1969	1978	biomarker	T201	UMLS:C0005516
27625705	1991	2001	Prevotella	T007	UMLS:C0242946
27625705	2003	2019	Faecalibacterium	T007	UMLS:C1229075
27625705	2024	2039	Bifidobacterium	T007	UMLS:C0005380